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Objectives: The spread of carbapenem-resistant Enterobacteriaceae (CRE) represents one of themostworrisome
problems for clinical medicine worldwide. In Italy, the Antibiotic-Resistance-Istituto Superiore di Sanita` surveil-
lance network, in collaboration with the Committee for Antimicrobial Agents of the Italian Society of Clinical
Microbiologists, promoted a study to investigate the carbapenem-resistance mechanisms, clonal relatedness
and capsular typing of a recent collection of carbapenem-resistant Klebsiella pneumoniae (CR-KP).
Methods: A total of 17 laboratories distributed across Italy collected all consecutive non-replicate CR-KP isolated
from invasive infections during two different study periods (2011–12 and 2013). Carbapenemase genes
were searched for by filter hybridization and confirmed by PCR and sequencing. KPC-producing K. pneumoniae
(KPC-KP) were typed by PFGE and MLST. Capsular types were identified by wzi gene typing.
Results: Of the collected K. pneumoniae isolates (n¼461), the overall proportion of CR-KP was 36.2% (n¼167).
The majority (97%) of the CR-KP were positive for the blaKPC gene. Among the KPC-KP population, nine different
STs were detected with the majority of isolates (94%) belonging to the clonal group (CG) 258. A subpopulation
that belonged to ST512 and showed an identical PFGE profile represented the majority (57%) of KPC-KP strains,
with a countrywide distribution. Capsular characterization showed the predominance of the wzi154, cps-2 cap-
sular type (88.8% of all CG258 strains). ST258 strains were associated with both cps-1 and cps-2 capsular types,
while ST512 was associated with cps-2 only.
Conclusions: Although a trend to a polyclonal evolution of the Italian KPC-KP was noted, this study showed that
the KPC-KP population remained largely oligoclonal with the wide diffusion of an ST512 lineage carrying cps-2
capsular type and producing the KPC-3 enzyme.
Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) are spreading
globally and have become endemic in several countries, including
Italy.1–3 CRE infections are difficult to treat due to their complex
multidrug-resistance phenotypes4,5 and are associated with
increased morbidity and mortality in comparison with infections
caused by carbapenem-susceptible strains.6 The most important
mechanism of carbapenem resistance in Enterobacteriaceae is
the production of carbapenemases, mostly of the KPC, VIM,
NDM and OXA-48 types, which exhibit notable geographical
variability.1,2,7,8 KPC-type carbapenemase-producing Klebsiella
pneumoniae (KPC-KP) emerged in 1996 in the USA9 and since
then has disseminated globally, becoming endemic in some
countries including Italy.7,10 The rapid and efficient dissemination
of KPC-KP has mostly been caused by the clonal expansion of
strains of clonal group (CG) 258 including ST258 and related
variants (e.g. ST512).7,11,12
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Recent comparative genomic studies revealed that ST258
comprises at least two different lineages, namely clade I
and clade II, which differ by a chromosomal region of 215 kb
carrying the capsular polysaccharide (CPS) gene cluster.12 –15
Characterization of the cps locus and prediction of the serotypes
(K type) is based on sequencing of the conserved wzi and/or wzc
genes, which are essential for CPS assembly and conserved in
all capsular types.16,17 Several multiplex-PCR approaches have
been developed for rapid characterization of the cps locus.18–20
Some K types are significantly associated with serious human
infections (e.g. K1) and CPS may be involved in the global success
of ST258.12,14
ST258 clade I carries the cps-1 gene cluster (characterized
by thewzi29 allele variant and associated with the K41 serotype),
while clade II carries the cps-2 gene cluster (characterized by
wzi154, untypeable with conventional methods).14 Furthermore,
a strong association between blaKPC22 and clade I, and between
blaKPC-3 and clade II, has been noted.
11,12,17,21
In Italy, the results from a cross-sectional nationwide survey
performed in 2011 showed that the KPC-KP represented the
majority (87%) of CRE and that the dissemination of KPC-KP
was mostly caused by strains of CG258, with a minority of strains
belonging to ST101.10 Further characterization of representative
strains from the same Italian nationwide survey showed that
the cps-2 variant of the CPS gene cluster was the most prevalent
among isolates of CG258 and was carried by both ST258 and
ST512 strains. In contrast, the cps-1 type was less widespread
and associated with isolates of ST258 only.17
In this work, we report the results of a countrywide survey that
aimed to investigate carbapenem-resistance determinants,
clonal relatedness and capsular types of carbapenem non-
susceptible K. pneumoniae isolated from invasive infections.
Methods
Study design
A multicentre cross-sectional collection of carbapenem-resistant
K. pneumoniae (CR-KP) was promoted by the Italian Antibiotic-
Resistance-Istituto Superiore di Sanita` (AR-ISS) surveillance network, in
collaboration with the Committee for Antimicrobial Agents of the Italian
Society of Clinical Microbiologists. A total of 17 laboratories, from 14 cities,
of the AR-ISS network (Figure 1) collected all consecutive non-replicate
clinical isolates of K. pneumoniae from blood or CSF with MICs .1 mg/L
for meropenem and/or imipenem during two different periods, 1
October 2011–31 March 2012 and 15 February 2013–15 June 2013. All
isolates that matched these criteria were considered as CR-KP for the
scope of this work. All laboratories provided information on the total num-
ber of consecutive non-duplicate clinical isolates of K. pneumoniae
observed during the collection period. Collected isolates were sent to ref-
erence laboratories for phenotypic and genotypic characterization.
Bacterial identification and phenotypic characterization
of resistance mechanisms
Bacterial identification and antimicrobial susceptibility testing were car-
ried out by the network laboratories using either a Phoenix Automated
Microbiology System (Becton Dickinson Diagnostic Systems, Sparks, MD,
USA) or a Vitek-2 System (bioMe´rieux, Marcy-l’E´toile, France). Reference
laboratories confirmed species identification by MALDI-TOF MS (Vitek-MS,
bioMe´rieux) and screened the collected isolates for carbapenemase
production by combination disc test usingmeropenemplus EDTA or phenyl-
boronic acid.22,23
Molecular characterization
The presence of themost prevalent carbapenemase genes (blaKPC, blaVIM,
blaIMP, blaNDM and blaOXA-48-like) was investigated by dot-blot DNA
hybridization using the method described by Srinivasan et al.24 All
hybridization-positive results were confirmed by PCR using primers and
conditions previously described.10 Amplification products were
sequenced by an external facility (Macrogen Inc., Seoul, Korea) and ana-
lysed using the BLAST program at NCBI (http://www.ncbi.nlm.nih.
gov/BLAST).
Isolates testing negative by the combination disc test and/or in a
hybridization experiment were further investigated for production of
carbapenemase by spectrophotometric assay on crude extracts.25
Clonal relatedness
Clonality was analysed for all KPC-KP by PFGE after digestion of genomic
DNA with XbaI as previously described10 and results were interpreted
according to the criteria reported by van Belkum et al.26 The same capital
letter (e.g. A) was assigned to identical PFGE profiles. PFGE profiles that
differed by ,4 bands were considered as profile variants (e.g. A1). PFGE
patterns differing by ≥4 bands were considered to belong to a different
profile (e.g. B). Representative isolates for each different PFGE profile or
profile variants were subjected to MLST analysis.27 STs were assigned
using the K. pneumoniae MLST web site (http://bigsdb.web.pasteur.fr/
perl/bigsdb/bigsdb.pl?db=pubmlst_klebsiella_seqdef_public).
Capsular type characterization
Capsular type characterization was performed for KPC-producing isolates
only. All isolates were tested using a previously developed multiplex PCR
able to recognize the two major capsular types associated with CG258
strains as well as those frequently associated with invasive disease or
pathogenicity.17 The wzi gene of the isolates that tested negative with
the multiplex PCR was amplified, sequenced and analysed according to




Proportion of CR-KP from reporting laboratories
The 17 laboratories of the AR-ISS network recorded, in the
two study periods, a total of 461 invasive infections caused
by K. pneumoniae (246 and 215 in the first and second study
periods, respectively). Details are reported in Table S1 (available
as Supplementary data at JAC Online). Overall, 167 isolates
(36.2%) were CR-KP, of which 164 (98%) were confirmed to be
carbapenemase-producing K. pneumoniae (CP-KP). The CP-KP pro-
portion observed in the second study period was slightly higher
than that observed in the first one (39.5% versus 33.3%, respect-
ively), but the difference was not statistically significant (P¼0.16).
Remarkable differences, however, were observed among propor-
tions in various laboratories and in local trends; only three labora-
tories did not report CR-KP isolates in both study periods. However,
two of these laboratories collected only very few K. pneumoniae
isolates during the study periods (Table S1).
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Characterization of carbapenem-resistance mechanisms
Overall, 162 out of the 167 CR-KP (97%) were positive for the
blaKPC gene and 2 (1.2%) for the blaVIM-1 metallo-b-lactamase
gene. The remaining three isolates (1.8%) tested negative for
phenotypic (including spectrophotometric assay) and genotypic
tests, suggesting the presence of a non-carbapenemase-
mediated mechanism of resistance. Other types of carbapene-
mases, including OXA-48 and NDM variants, were not detected.
Regarding the blaKPC types, the majority of the 162 KPC-KP
(87%) carried the blaKPC-3 variant, while the remaining (13%)
carried the blaKPC-2 variant.
KPC-KP population analysis
Nine different STs were detected among KPC-KP (ST512, ST258,
ST1879, ST101, ST1633, ST15, ST307, ST45 and ST2032) with
the majority of isolates (94%) belonging to CG258 (ST258 and
its single-locus variants ST512 and ST1879) (Table 1). Isolates of
CG258 were found in all centres reporting KPC-KP isolates with a
countrywide distribution (Table 1 and Figure 1), confirming the
spreading ability of these lineages. Although not statistically sig-
nificant, an increment in the proportion of ST512 versus ST258
was observed in themost recent study period (42% in 2013 versus
28% in 2011–12). Overall, other STs accounted for 6% of the
KPC-KP population and were sporadically detected with a more
restricted geographical distribution (Table 1). Two novel STs,
ST2032 and ST1879, were described, while ST1633 (a single-locus
variant of ST101) was reported for the first time in Italy.
ST512, ST258 and ST15 showed 7, 12 and 3 PFGE profile
variants, respectively (Table 1 and Figure S1). The two major
PFGE profiles, A and B, included isolates belonging to both
ST258 and ST512 (Table 1 and Figure S1). However, the majority
(57%) of KPC-KP isolates belonged to the same PFGE A2 variant
of ST512 that was detected in 10 out of 14 centres reporting
KPC-KP isolates (Table 1 and Figure 1).
Figure 1. Geographical location of the 17 laboratories participating in the survey. The KPC-KP STs detected in different laboratories are indicated by
different colours. Cities were as follows: 1, Alessandria; 2, Ancona; 3, Bergamo; 4, Catania; 5, Cosenza; 6, Foggia; 7, Lecco; 8–10, Milan; 11, Naples;
12 and 13, Rome; 14, San Remo; 15, Sienna; 16, Trento; and 17, Venice. This figure appears in colour in the online version of JAC and in black and
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Characterization of the cps gene clusters in KPC-KP
isolates
All the 152 strains belonging to CG258 were typeable using the
multiplex PCR method.17 Of these, 88.8% carried cps-2 and
11.2% carried cps-1. The cps-2 capsular type was detected in all
but one centre reporting KPC-KP isolates and was associated with
isolates belonging to ST258, ST512 and ST1879, while cps-1 was
associatedwith ST258 strains only, with a distribution restricted to
centres located in northern Italy (Table 1). ST512 was invariably
associated with the cps-2 capsular type.
During the study periods a significant increment in the percent-
age of isolates with cps-2 capsular type among CG258 strains was
documented (83.5% in 2011–12 versus 93.7% in 2013; P,0.05).
According to what has been previously reported,11,12,17,21 cps-1
was always associated with the presence of blaKPC-2, and cps-2
with the presence of blaKPC-3. The cps-1 and cps-2 capsular gene
clusters were restricted to CG258 strains.
The remaining strains that were untypeable (n¼10) by the
multiplex PCR method belonged to STs not included in CG258.
ST101 and its single-locus variant ST1633 carried the wzi137
variant associated with the K17 serotype. ST307 and ST2032
strains carried wzi173 and wzi174 (two variants not previously
associated with specific serotypes), respectively. The remaining
five strains belonging to ST15 and ST45 carried wzi24 or wzi101
(the predicted K24 serotype) (Table 1).
Discussion
The results of this survey confirmed the highly endemic nature of
CR-KP across the entire Italian territory. The observed proportions
were overall similar to those reported by the EARS-NET surveil-
lance report for the same years (29.1% for 2012 and 34.7% for
2013).28 As reported in the 2011 Italian survey,10 KPC production
continued to represent the most frequent mechanism of resist-
ance to carbapenems in K. pneumoniae, while other mechanisms
remained in the background or were not detected.
Although the sporadic detection of several non-CG258 STs
(ST101, ST15, ST307, ST45, ST1633 and ST2032) was reported,
Table 1. Correspondence among ST, PFGE and KPC enzyme variants produced by the 162 KPC-KP; the total numbers of isolates that belonged to specific
ST and PFGE profiles are also reported
ST PFGE type Total number of isolates Centres wzi variant (cps type) KPC variant
512 A0 1 1 154 (cps-2) KPC-3
A1 9 5;6;8 154 (cps-2) KPC-3
A2 93 1;2;6;8;11;12;13;14;15;17 154 (cps-2) KPC-3
A3 5 4;12;13 154 (cps-2) KPC-3
A4 1 6 154 (cps-2) KPC-3
A5 1 14 154 (cps-2) KPC-3
B0 2 3;14 154 (cps-2) KPC-3
258 A6 5 1 29 (cps-1) KPC-2
A7 14 4;6;8;17 154 (cps-2) KPC-3
A8 3 1;5 154 (cps-2) KPC-3
A9 1 4 154 (cps-2) KPC-3
A10 3 8;9 29 (cps-1) KPC-2
B1 2 8 29 (cps-1) KPC-2
B2 3 4 154 (cps-2) KPC-3
B3 2 1 29 (cps-1) KPC-2
B4 2 3 29 (cps-1) KPC-2
B5 1 3 29 (cps-1) KPC-2
B6 2 3;8 29 (cps-1) KPC-2
B7 1 4 154 (cps-2) KPC-3
1879 A11 1 6 154 (cps-2) KPC-3
101 C0 2 5;14 137 KPC-2
15 D0 1 1 24 KPC-3
D1 1 1 24 KPC-3
E0 2 14 24 KPC-2
307 F0 1 3 173 KPC-3
2032 F1 1 13 174 KPC-3
1633 G0 1 17 137 KPC-3
45 H0 1 12 101 KPC-3
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the KPC-KP population structure remained largely oligoclonal,
with 94% of isolates represented by CG258 strains and the
majority of them belonging to a single PFGE subtype.
Nevertheless, compared with the previous Italian survey,
where only CG258 and strains of ST101 were reported (the latter
sporadically), a trend to a polyclonal evolution of the KPC-KP
population was observed, as also previously reported at a local
level.29,30 This could suggest an evolution of the KPC-KP epidemic
similar to what has been observed in Greece, where the later
phases of the KPC-KP epidemic were associated with the diffusion
of several STs different from the original epidemic ST258 clone.31
Considering this ongoing epidemiological evolution, characteriza-
tion of a more recent collection of KPC-KP from the same centres
will be of interest. It would also be of interest to analyse the types
and diversity of KPC-encoding plasmids associated with the
predominant KPC-KP clones and compare them with those
circulating in the early stages of the Italian KPC-KP epidemic.32
Our study also confirmed, on a broader scale and over a longer
time frame, the presence of two distinct cps types among KPC-KP
strains of CG258.17,21 ST258 was associated with both cps-1 and
cps-2, while ST512 was always associated with cps-2. To further
support this finding, we determined in silico the wzi allelic variant
of the 455 CG258 genomes available in the nr and wgs NCBI
databases (accessed on 15 January 2016) and confirmed the
predominance of the wzi154 variant (cps-2) (76% of the CG258
sequenced genomes). This analysis also confirms the invariable
association of ST512 with cps-2 and suggests that ST258
wzi154 could be the ancestor of ST512.
The reasons for the predominance of strains with the cps-2
capsular type remain to be clarified. However, a different virulence
potential could contribute to the success of a variant within a
clone. In fact, the lower virulence potential of cps-2 ST258 strains
compared with cps-1 ST258 strains, as indicated by results of pre-
viousworks carried out in theGalleriamellonellamodel, could play
a role in this phenomenon.21,33 In this work we analysed isolates
from invasive infections only. Further investigation on isolates
from colonization and other types of infection would be of interest
to study a possible correlation between the different virulence
potential of the two capsular types and their ability to cause col-
onization and infections.
Results from capsular typing also underlined the presence in
Italy of ST15 strains carrying wzi24 associated with K24 and
belonging to CG14. Strains belonging to CG14 of the K2 and K24
serotypes usually carry a relevant virulence factor content and
have been associated with serious human infections.34 This find-
ing underscores the potential threat represented by the emer-
gence and diffusion of carbapenem-resistance clones with
increased virulence potential.35,36
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